Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
risperidone + clozapine
- Development stage
- Unknown
- Lead developer
- Shanghai Mental Health Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Risperidone + clozapine is a combination therapy consisting of two atypical antipsychotics used primarily for the management of treatment-resistant schizophrenia. Clozapine is considered the gold standard for patients who fail to respond to other antipsychotics, but a significant portion of patients remain symptomatic. The addition of risperidone, which has a high affinity for dopamine D2 and serotonin 5-HT2A receptors, is intended to provide synergistic effects by enhancing dopaminergic blockade and improving clinical outcomes. This specific combination has been the subject of clinical investigation by the Shanghai Mental Health Center to determine the optimal augmentation strategy for patients with treatment-resistant schizophrenia.
- Other names
- Risperidone with ClozapineClozapine augmented with Risperidone
02
Targets
DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)ADRA2A (α2A)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on risperidone + clozapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on risperidone + clozapine.